HMGB1 Acts in Synergy with Lipopolysaccharide in Activating Rheumatoid Synovial Fibroblasts Via P38 MAPK and NF-κB Signaling Pathways
Overview
Pathology
Affiliations
Synovial fibroblasts (SF) play a central role in the inflammatory and destructive process in rheumatoid arthritis (RA). High-mobility group box chromosomal protein 1 (HMGB1) or lipopolysaccharide (LPS) alone failed to induce significant changes in proliferation of cultured SF from RA patients, but premixed HMGB1 with LPS (HMGB1-LPS) significantly facilitated SF proliferation. HMGB1 alone failed to induce IL-6, MMP-3, and MMP-13 production in cultured SF but greatly enhanced LPS-induced expression of IL-6, MMP-3, and MMP-13 at both mRNA and protein levels. HMGB1-LPS synergistically upregulated TLR4 and receptor for advanced glycation endproducts (RAGE) expression on the surface of SF. Both blockers of TLR4 and RAGE significantly inhibited the synergistic effects of HMGB1-LPS on the production of IL-6 and MMPs, but blocking antibodies to TLR2 failed. HMGB1-LPS synergistically increased intracellular levels of phosphorylated p38 and phosphorylated I κ B. Furthermore, both NF- κ B inhibitor Bay11-7085 and p38 inhibitor SB203580 significantly suppressed the enhanced production of IL-6 and MMPs induced by HMGB1-LPS. In conclusion, HMGB1 acts in synergy with LPS to upregulate TLR4 and RAGE expression on the surface of SF in RA and then to augment IL-6, MMP-3, and MMP-13 production, which depends on p38 MAPK and NF-κB activation.
The Role of Alarmins in the Pathogenesis of Rheumatoid Arthritis, Osteoarthritis, and Psoriasis.
Kielbowski K, Stanska W, Bakinowska E, Rusinski M, Pawlik A Curr Issues Mol Biol. 2024; 46(4):3640-3675.
PMID: 38666958 PMC: 11049642. DOI: 10.3390/cimb46040228.
Establishment and comparison of human term placenta-derived trophoblast cells†.
Vidal Jr M, Radnaa E, Vora N, Khanipov K, Antich C, Ferrer M Biol Reprod. 2024; 110(5):950-970.
PMID: 38330185 PMC: 11484515. DOI: 10.1093/biolre/ioae026.
Ozkul B, Sever I, Yigitturk G, Elgormus C, Gur S, Erbas O Ulus Travma Acil Cerrahi Derg. 2023; 29(9):963-971.
PMID: 37681716 PMC: 10560817. DOI: 10.14744/tjtes.2023.73580.
Li J, Zhang X, Guo D, Shi Y, Zhang S, Yang R Front Pharmacol. 2023; 14:1113810.
PMID: 36992829 PMC: 10040578. DOI: 10.3389/fphar.2023.1113810.
Wang Y, Wang L, Hu F, Zou M, Luo R, Sun Y Cells. 2022; 11(18).
PMID: 36139393 PMC: 9496866. DOI: 10.3390/cells11182817.